Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Vesprini

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Molecular Genetics and Metabolism|February 13, 2001
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer riskH Jernström, W Chu, D Vesprini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 20, 2024
Comparing Interfractional Stability of Heart Dose Among Three Breath-Hold Radiotherapy Techniques in Breast CancerA W Chan, A Hoang, H Chen, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 1, 2011
Expression of HER2neu in ductal carcinoma in situ is associated with local recurrenceK Han, S Nofech-Mozes, S Narod, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 29, 2021
Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort StudyA Swaminath, P Cheung, R M Glicksman, et al.
Familial Cancer|October 24, 2003
Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implicationsT Pal, N Hamel, D Vesprini, et al.
British Journal of Cancer|May 19, 2000
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinomaG Liu, P Ghadirian, D Vesprini, et al.
American Journal of Human Genetics|March 20, 2001
HPC2 variants and screen-detected prostate cancerD Vesprini, R K Nam, J Trachtenberg, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 10, 2022
Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function OutcomesR M Glicksman, P Cheung, R Korol, et al.
Urology|February 13, 2001
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progressionR K Nam, A Toi, D Vesprini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 17, 2017
Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility AnalysisJ Helou, S Torres, H B Musunuru, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Molecular Genetics and Metabolism|February 13, 2001
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer riskH Jernström, W Chu, D Vesprini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 20, 2024
Comparing Interfractional Stability of Heart Dose Among Three Breath-Hold Radiotherapy Techniques in Breast CancerA W Chan, A Hoang, H Chen, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 1, 2011
Expression of HER2neu in ductal carcinoma in situ is associated with local recurrenceK Han, S Nofech-Mozes, S Narod, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 29, 2021
Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort StudyA Swaminath, P Cheung, R M Glicksman, et al.
Familial Cancer|October 24, 2003
Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implicationsT Pal, N Hamel, D Vesprini, et al.
British Journal of Cancer|May 19, 2000
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinomaG Liu, P Ghadirian, D Vesprini, et al.
American Journal of Human Genetics|March 20, 2001
HPC2 variants and screen-detected prostate cancerD Vesprini, R K Nam, J Trachtenberg, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 10, 2022
Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function OutcomesR M Glicksman, P Cheung, R Korol, et al.
Urology|February 13, 2001
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progressionR K Nam, A Toi, D Vesprini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 17, 2017
Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility AnalysisJ Helou, S Torres, H B Musunuru, et al.
Pageof 4